Alpha Cognition (ACOG) stock price, chart and financials

Price chart

Revenue (trailing twelve months)

$15.3M

Revenue (quarter)

$6.1M

Revenue growth (year over year)

+267.56%

Gross profit (trailing twelve months)

$13.7M

Gross margin

89.92%

Net income (trailing twelve months)

−$21.0M

Net income (quarter)

−$8.8M

Net income growth (year over year)

+33.41%

Net margin

−137.70%

Return on equity

−49.53%

EPS (trailing twelve months)

−$0.94

Book value per share

$2.43

P/E (trailing twelve months)

—

Price to book

3.56

Debt to assets

17.91%

Payout ratio

—

Dividend yield

—

Company profile

Alpha Cognition Inc is a biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimers disease, for which there are limited or no treatment options. The Companies current focus is on the commercial manufacturing and sales of ZUNVEYL oral tablet formulation. The Companies commercial development program for ZUNVEYL is focused on building a long-term care commercial team that can focus on providing key points of differentiation, exploiting key issues with existing Acetylcholinesterase inhibitors treatments, and seeking potential licensing partners for other additional indications and new formulations.

• Is Alpha Cognition (ACOG) profitable?

  No. Alpha Cognition reported a net loss of $21.0M over the trailing twelve months.

• How much revenue does Alpha Cognition (ACOG) make?

  Alpha Cognition generated $15.3M in revenue over the trailing twelve months, up 267.56% year over year.

• How do I buy stock in Alpha Cognition (ACOG)?

  ACOG trades commission-free with a Light Horse Securities brokerage account — from the mobile app, the web at Light Horse Dashboard, the trading API, or an AI agent connected over MCP. The trade panel on this page places the order once you are signed in.